RAD-140 (Testolone)

RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). Radius took it into oncology rather than into muscle wasting, and the only registered human trial is a phase 1 study in postmenopausal women with hormone receptor positive metastatic breast cancer. It is not approved by any regulator.

The molecule binds the androgen receptor and acts as an agonist, changing which androgen-responsive genes are transcribed. The human phase 1 study used sex hormone binding globulin and prostate-specific antigen as markers of that engagement and saw sex hormone binding globulin fall in all 18 evaluable patients and prostate-specific antigen rise in 16 of 20, with paired tumor biopsies confirming receptor engagement (PMID: 34565686).

Preclinical work covers three separate claims. For neuroprotection, RAD-140 reduced apoptotic cell death in cultured rat hippocampal neurons and protected hippocampal neurons in kainate-lesioned male rats, with the effect depending on MAPK signaling (PMID: 24428527). For oncology, it inhibited growth of androgen receptor positive and estrogen receptor positive breast cancer models (PMID: 28974548). For muscle, a study in young male Sprague-Dawley rats found increased muscle fiber cross-sectional area in unloaded animals but no additional benefit when combined with functional overload, and no change in cortical or trabecular bone over 14 days (PMID: 40680216). Two mouse studies point the other way on health span: in female mice, ten weeks of RAD140 increased frailty and mortality risk and failed to improve strength (PMID: 37758180), and a later study in older male and female mice again reported an effect on frailty (PMID: 40158703).

The human safety signal is the clearest reason this compound is not a casual purchase. In the phase 1 cancer study, the most frequent treatment-emergent adverse events were raised aspartate aminotransferase in 59.1 percent, raised alanine aminotransferase in 45.5 percent and raised total bilirubin in 27.3 percent, and grade 3 or 4 events occurred in 72.7 percent of the 22 patients (PMID: 34565686). Outside trials, biopsy-confirmed cholestatic drug-induced liver injury after RAD-140 has been reported repeatedly, with peak total bilirubin far above normal and recovery taking months (PMID: 36561105, PMID: 36945289, PMID: 39328701, PMID: 36978171, PMID: 38444893). There are also cardiac case reports: acute myocarditis (PMID: 35233331), myopericarditis in a 16-year-old boy after a first dose (PMID: 39157568) and heart failure (PMID: 38864168).

RAD140 is named in FDA warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025), and it is prohibited in sport at all times under the World Anti-Doping Agency anabolic agents class (PMID: 28137616).

RAD-140 (Testolone) is available in capsule form.

Compare prices, payment methods, shipping, and COA scores across 1 vendor.

1 of the vendors BodyHackGuide tracks list RAD-140 (Testolone) (1 listing). The lowest listed price BodyHackGuide has recorded for RAD-140 (Testolone) is $84.99. No RAD-140 (Testolone) listing recorded as in stock carries a milligram count, so BodyHackGuide states no price per milligram for RAD-140 (Testolone).

BodyHackGuide holds 2 third-party certificate records for RAD-140 (Testolone), from . No editor has read any of BodyHackGuide's 2 certificate records for RAD-140 (Testolone). The laboratory named on BodyHackGuide's RAD-140 (Testolone) certificate records is Freedom Diagnostics Testing, and the newest test date on them is 11 September 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.